Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Vaxcyte, Inc. reported a larger net loss for 2025 while advancing its late-stage pneumococcal vaccine programs and strengthening its balance sheet. The company posted a 2025 net loss of $766.6 million, driven mainly by higher research and development spending of $794.3 million as it moved the VAX-31 adult and infant programs into Phase 3 and Phase 2, respectively, and expanded manufacturing readiness.
Cash, cash equivalents and investments were $2.44 billion as of December 31, 2025, not including approximately $600.2 million in net proceeds from a $632.5 million equity offering in February 2026. Vaxcyte highlighted three ongoing Phase 3 adult studies for VAX-31, completed enrollment of a 900-infant Phase 2 study, and plans to start a Phase 1 adult trial for its Group A Strep candidate VAX-A1 in 2026.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting a significant ownership stake in Vaxcyte Inc. common stock. As of 12/31/2025, it reported beneficial ownership of 11,296,333 shares, representing 8.6% of Vaxcyte’s outstanding common stock.
The firm reported sole voting power over 11,064,015 shares and sole dispositive power over 11,296,333 shares, with no shared voting or dispositive power. It states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Vaxcyte, and it expressly denies beneficial ownership in a legal-admission sense.
Vaxcyte, Inc. entered into an underwriting agreement to issue and sell 11,000,000 shares of common stock at $50.00 per share to the public, with underwriters purchasing at $47.50 per share. The company granted underwriters a 30-day option to buy up to 1,650,000 additional shares, which they exercised in full. Including this option, Vaxcyte expects net proceeds of approximately $600.2 million after underwriting discounts, commissions and estimated expenses. The offering, made under an effective Form S-3 shelf registration, closed on February 2, 2026 and was led by a syndicate of major investment banks.
Vaxcyte, Inc. is offering 11,000,000 shares of common stock at $50.00 per share, with gross proceeds of $550,000,000 and estimated net proceeds of about $521.9 million after fees and expenses.
The underwriters have a 30-day option to purchase up to 1,650,000 additional shares. As of September 30, 2025, Vaxcyte had 130,029,111 shares outstanding; after this offering, that figure would be 141,029,111 shares on an as-adjusted basis. The company reports preliminary cash, cash equivalents and investments of approximately $2.4 billion as of December 31, 2025, and its capitalization table shows cash, cash equivalents and investments increasing from $2,670.6 million to $3,192.4 million on an as-adjusted basis.
The offering creates immediate dilution for new investors: historical net tangible book value was $21.61 per share, rising to $23.62 per share after the deal, implying dilution of $26.38 per share at the $50.00 offering price. Vaxcyte plans to use the proceeds, together with existing cash, to fund its vaccine development programs and for general corporate purposes, while noting that the funds will not be sufficient to take any product candidate through regulatory approval.
Vaxcyte, Inc. plans a primary offering of common stock and pre-funded warrants, using a Nasdaq-listed common share price as the reference for warrant pricing. The pre-funded warrants carry a $0.001 exercise price and do not expire until fully exercised.
The company is a clinical-stage vaccine developer using a cell-free protein synthesis platform to design complex vaccines for serious bacterial diseases. It preliminarily expects to report about $2.4 billion in cash, cash equivalents and investments as of December 31, 2025 and intends to use new proceeds to strengthen its balance sheet and fund vaccine development programs.
Vaxcyte, Inc. director and CEO Grant Pickering reported an internal share transfer involving company common stock. On January 14, 2026, an entity associated with him transferred 100,000 shares of common stock to an irrevocable trust for estate planning purposes, with a reported price of $0 per share, indicating this was not an open‑market sale. The footnote explains that he no longer has a pecuniary interest in those shares and therefore disclaims beneficial ownership.
Following the transaction, 400,908 common shares are reported as directly owned. In addition, 136,215 common shares are held by a trust for the benefit of his son and another 136,215 common shares are held by a trust for the benefit of his daughter, both reported as indirectly owned through children’s trusts.
Vaxcyte, Inc. reported an insider share transfer involving its President and CFO, Andrew Guggenhime. On 01/14/2026, 61,850 shares of common stock were moved from his direct holdings to ALG 2025 GRAT HOLDINGS LLC at a reported price of $0 per share. The filing notes that he is the sole member and manager of this LLC, and that the LLC is wholly owned by a grantor retained annuity trust for which he is the sole annuitant and trustee.
After the transaction, Guggenhime directly held 62,459 shares of Vaxcyte common stock and indirectly held 61,850 shares through ALG 2025 GRAT HOLDINGS LLC.
Vaxcyte, Inc. director Olivier Brandicourt reported receiving new equity awards. On January 15, 2026, he was granted 1,357 shares of Common Stock underlying restricted stock units, which will fully vest on the earlier of June 12, 2026 or the day before the next annual stockholder meeting, subject to his continuous service.
He was also granted a stock option for 6,750 shares of Common Stock, which vests monthly and will be fully vested on the same schedule, also conditioned on continued service. After the RSU grant, he directly beneficially owned 2,505 shares of Common Stock, and he held 6,750 stock options.
Vaxcyte (PCVX) reported Q3 2025 financial results. The company posted a net loss of $212.8 million, driven by higher operating expenses as R&D rose to $209.9 million and G&A reached $32.4 million. Year-to-date, net loss was $520.1 million.
Liquidity remains strong with $2.67 billion in cash, cash equivalents and investments as of September 30, 2025 (cash and cash equivalents $281.1 million, short‑term investments $1.43 billion, long‑term investments $959.3 million). Operating cash use totaled $430.7 million for the first nine months.
Vaxcyte expanded manufacturing capacity and supply: it maintains a long‑term arrangement with Lonza and, on September 24, 2025, entered a 15‑year commercial manufacturing agreement with Thermo Fisher for drug product. Non‑cancelable purchase commitments to key manufacturing partners totaled $631.7 million. Shares outstanding were 130,029,111 at September 30, 2025 and 130,906,263 at October 31, 2025.
Vaxcyte, Inc. (PCVX) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The company states the information in Items 2.02 and 9.01, including Exhibit 99.1, is furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act. Vaxcyte’s common stock trades on The Nasdaq Stock Market LLC under the symbol PCVX.